Quarterly ResultMay 6, 2026, 07:02 AM
EyePoint Q1 Net Loss $84.8M; DURAVYU Phase 3 Trials on Track
AI Summary
EyePoint, Inc. announced its first quarter 2026 financial results, reporting a net loss of $84.8 million on $0.7 million in revenue, a significant decrease from the prior year. Concurrently, the company provided positive updates on its DURAVYU Phase 3 clinical trials, with wet AMD data expected mid-2026 and DME enrollment rapidly advancing towards Q3 2026 completion. EyePoint maintains a cash position of $223 million, providing a runway into Q4 2027.
Key Highlights
- Phase 3 wet AMD trials (LUGANO, LUCIA) on track for topline data beginning mid-2026.
- Phase 3 DME trials (COMO, CAPRI) over one-third enrolled, completion expected Q3 2026.
- Total net revenue for Q1 2026 was $0.7 million, down from $24.5 million in Q1 2025.
- Operating expenses increased to $87.9 million in Q1 2026 from $73.3 million in Q1 2025.
- Net loss for Q1 2026 was $84.8 million, or $(0.99) per share.
- Cash and investments totaled $223 million as of March 31, 2026.
- Cash runway expected into Q4 2027, beyond key wet AMD milestones in 2026.